FDA Approves Weight-Loss Drug to Treat Obstructive Sleep Apnea - GV Wire
The FDA approved Zepbound, the first prescription drug for obstructive sleep apnea, for people with obesity and moderate to severe sleep apnea. Studies showed improvement in symptoms with Zepbound compared to a placebo. The drug's compound, tirzepatide, also aids weight loss and is used in diabetes treatment. The approval may increase demand for obesity medications and influence insurance coverage.
Highlighted Terms
Related News
The FDA approved Zepbound, the first prescription drug for obstructive sleep apnea, for people with obesity and moderate to severe sleep apnea. Studies showed improvement in symptoms with Zepbound compared to a placebo. The drug's compound, tirzepatide, also aids weight loss and is used in diabetes treatment. The approval may increase demand for obesity medications and influence insurance coverage.